Ftse Mib
33.668,59
0,11%
DAX
17.760,35
-0,15%
S&P 500
5.022,21
-0,58%
NASDAQ Composite
15.683,37
0,00%
Bitcoin
62.332,95
1,73%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistente personale
Home Investire Azioni U.S.A. NASDAQ Amgen Inc (AMGN) Amgen Inc (AMGN) Notizie

Amgen Inc

AMGN
264,07
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 14:09:09
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
16/4/202423:26PRNUSAMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
09/3/202418:20PRNUSAMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD..
08/3/202423:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202423:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202422:00PRNUSAMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
29/2/202422:00PRNUSAMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE..
26/2/202415:00PRNUSAMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN..
19/2/202422:00PRNUSAMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
14/2/202422:23EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
13/2/202401:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:00PRNUSAMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE..
07/2/202411:49IHMARKETNEWSMoody’s Downgrades NYCB to Junk Status, Ford Declares..
06/2/202423:05IHMARKETNEWSU.S. Stocks Finish Choppy Trading Day Modestly Higher
06/2/202422:20EDGAR2Form 8-K - Current report
06/2/202422:01PRNUSAMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL..
06/2/202412:27IHMARKETNEWSUS Index Futures Mixed, Oil Prices Edge Higher
02/2/202422:25IHMARKETNEWSU.S. Stocks Extend Thursday’s Rally On Upbeat Meta, Amazon..
01/2/202422:00PRNUSAMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR..
29/1/202411:00PRNCAdeCODE genetics: A sequence variant that increases risk of..
17/1/202412:33IHMARKETNEWSWall Street Highlights: Tesla Cuts Prices in Germany,..
10/1/202416:12DJNXeris Biopharma Shares Climb 12% on Amgen License Agreement
10/1/202414:53DJNXeris Biopharma Reaches License Agreement With Amgen On..
10/1/202414:45IHNWGLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons
03/1/202422:00PRNUSAMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE..
02/1/202417:42DJNAmgen On Pace for Record High Close -- Data Talk
26/12/202315:00PRNUSAMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS®..
20/12/202302:38EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/12/202315:53DJNAmgen Names James Bradner Chief Scientific Officer
14/12/202315:16EDGAR2Form 8-K - Current report
14/12/202315:00PRNUSAMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE..
14/12/202311:00PRNUSAMGEN TO SPONSOR THE IRISH OPEN
13/12/202322:40DJNAmgen Gets FDA Priority Review For Lung Cancer Treatment
13/12/202322:00PRNUSFDA Grants Priority Review to Amgen's Tarlatamab Application..
13/12/202312:30IHMARKETNEWSCal-Maine Avian Flu Outbreak Impact, Amgen Hikes Dividend..
12/12/202322:41DJNAmgen Raises Dividend 5.6% To $2.25 A Share
12/12/202322:00PRNUSAMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO..
08/12/202315:00PRNUSAMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023
05/12/202301:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202301:40EDGAR2Form 144 - Report of proposed sale of securities
30/11/202302:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/11/202322:00PRNUSAMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE
14/11/202302:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: Min: Max:
Chiusura: 264,07

La tua Cronologia

NASDAQ
AMGN
Amgen
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network